CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2021; 81(12): 1301-1306
DOI: 10.1055/a-1541-7964
GebFra Science
Statement/Stellungnahme

Recommendations of the AGG (Section Maternal Disease) for Myasthenia Gravis in Pregnancy

Article in several languages: English | deutsch
Maritta Kühnert
1   Obstetrics, UFK Marburg, Marburg, Germany
,
Markus Schmidt
2   Gynecology & Obstetrics, Sana Kliniken Duisburg GmbH, Duisburg, Germany
,
Bettina Kuschel
3   Frauenklinik und Poliklinik, Klinikum rechts der Isar, Technische Universität München, München, Germany
,
Ute Margaretha Schäfer-Graf
4   Perinatalzentrum, Klinik für Gynäkologie und Geburtshilfe, Berlin, Germany
› Author Affiliations

Abstract

Myasthenia gravis is an autoimmune disease with a range of clinical presentations which manifest as combinations of weakness of the ocular, bulbar, and respiratory muscle groups and muscles of the extremities. Young women of reproductive age are most commonly affected. Preconception planning, the impact of pregnancy, prepartum management, drug therapy in pregnancy, myasthenic and cholinergic crises, fetal monitoring, peripartum management including analgesia and anesthesia during labor and cesarean section as well as neonatal management and neonatal myasthenia gravis are described here and the appropriate recommendations are given.



Publication History

Received: 18 June 2021

Accepted after revision: 29 June 2021

Publication Date:
08 December 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany